Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V. Negrão, Sandip Pravin Patel, Susan C. Scott et al.|Cancer Discovery|2023Cited by 181
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancerGiannis Mountzios, Petros Christopoulos, Epaminontas Samantas et al.|ESMO Open|2021Cited by 93
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel W. Neal, Thomas Newsom-Davis, Nick Pavlakis et al.|Journal of Clinical Oncology|2024Cited by 57
Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression and Survival in Operable Squamous-Cell Laryngeal CancerGiannis Mountzios, George Fountzilas, Ioannis Kostopoulos et al.|PLoS ONE|2013Cited by 45
Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology GroupHelena Linardou, George Fountzilas, Nikolaos Spanakis et al.|Cancers|2021Cited by 41